Hepatitis B insurance for the newborn.
Explore the source record for details and available documents.
Evaluation Studies as Topic↗
Biomedical subjects
V Chandeying
Publications and source records attributed to V Chandeying.
Merkel cell carcinoma of the vulva: a case report.
The clinical and pathologic findings of Merkel cell carcinoma of the vulva were reported. The light microscopic findings of sheets of small, uniform cells were consistent with a diagnosis of neuroendocrine tumor. The electron microscopic characteristics revealed membrane-bound secretory granules, confirmed the diagnosis of Merkel cell carcinoma. Regional lymphnode metastases were present at the time of initial surgery and the adjunctive radiotherapy was also given. This case was unusual because Merkel cell carcinoma was usually found on the face, extremities and buttocks.
Adult↗
Incidental appendectomy at cesarean section: a prospective study.
In conclusion, the present study describes a controlled series and demonstrates the safety of incidental appendectomy at cesarean section. A slight increase in operative time accompanied appendectomy group, but the length of hospital stay and postoperative morbidity were not different. It's our recommendation that at cesarean section if the abnormal appendix is found, appendectomy should be done. Normal appendix can also be removed whenever the opportunity presents in non-risk patients.
Adult↗
Sublingual buprenorphine and pethidine for immediate postoperative pain relief in major gynecologic surgery: a comparative study.
The analgesic effect of sublingual buprenorphine 0.4 mg has been compared with pethidine 1 mg/kg given intramuscularly in 80 patients following major gynecologic operation. The results indicate a slower onset of action for sublingual buprenorphine in the first two hours (p less than 0.001), but it has a much longer duration and is more effective for pain relief (p less than 0.001) than pethidine. The main side-effects were nausea and vomiting which occurred after both treatments but with no significant difference.
Administration, Sublingual↗
Endometriosis during pregnancy: report of 3 cases.
Three cases of asymptomatic pelvic endometriosis during pregnancy were reported. All cases denied abnormal vaginal bleeding, dyspareunia or dysmenorrhea; but only one case was noted to have a problem of infertility. Conservative operations were performed at the second trimester and during cesarean section with an uneventful postoperative course. Cyclic menses have been resumed.
Adult↗
Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: response of chlamydia-positive and chlamydia-negative forms.
The treatment of mucopurulent cervicitis in nonpregnant women was evaluated in a randomized study. Subjective and objective criteria were used to assess the response of cervicitis to therapy. Forty-three patients (Group I) were treated with Ofloxacin, 100 mg orally twice daily for 10 days, and forty-five patients (Group II) were treated with Ofloxacin, 200 mg orally twice daily for 7 days. Both produced significant improvement in subjective and objective signs of cervicitis; decreasing clinical symptoms, eliminating mucopurulent endocervical findings, and eradicating C. trachomatis. Overall, of the chlamydia-positive form the complete response of Ofloxacin treatment in mucopurulent cervicitis was 18 (60.0%), the partial response was 10 (33.3%), and resistance was 2 (6.6%) of the 30 patients (p = 0.6592). Of the chlamydia-negative form the complete response was 38 (65.5%), the partial response was 20 (34.5%) of the 58 patients (p = 0.9463). C. trachomatis eradication was satisfactory between both treatment regimens; 28 (93.3%) of the 30 women in chlamydia-positive form. This trial shows that both regimens are also beneficial in the treatment of mucopurulent cervicitis either C. trachomatis positive or C. trachomatis negative, and do not differ significantly between both groups (p = 0.1375). No side effects were observed.
Adult↗
Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
PURPOSE: The purpose of this 2-year follow-up study was to investigate the long-term effect of Remune as monotherapy for HIV-1 infection. BACKGROUND: Participants previously enrolled in the phase II double-blind, randomized, adjuvant-controlled study of the HIV-1 Immunogen (Remune) were followed for 2 years. Open-label immunization with Remune monotherapy was given to each participant every 12 weeks. Remune, a gp 120-depleted HIV-1 that was inactivated in beta-propiolactone and irradiation, was emulsified with mineral oil (incomplete Freund's adjuvant). METHOD: In Study 2101B, the effect of four doses of Remune given every 12 weeks over 40 weeks was compared to placebo in 297 asymptomatic type E HIV-infected patients [Churdboonchart et al., 2000]. A group of 17 volunteers were separated into a subset study and another 57 were excluded from analysis due to discontinuation or addition of other treatments. This 2-year follow-up study continued with open-label dosing of HIV-1 Immunogen every 12 weeks for the remaining 223 patients. Changes in CD4+ cells, CD8+ cells, and body weight were monitored at each patient visit. RESULTS: Overall, immunizations were safe; common adverse events were tolerable injection site reactions. CD4+ T-cell counts remained stable over the 132-week observation period for this cohort with a slight increase of 36.01 cells/microL. CD8+ T-cell counts showed an increase from baseline during the follow-up period (415.21 cells/microL). Furthermore, we also observed an increase in body weight from baseline (1.08 kg) at week 132. In addition, baseline CD4 count appeared to predict CD4 count at week 132 (slope = 0.31, p <.0001). CONCLUSION: These results suggest that long-term treatment of HIV-1 infection with Remune monotherapy is safe and results in a stabilization of CD4+ counts. Furthermore, it is likely that HIV-1 therapeutic immunization may show its greatest clinical benefit in participants with higher CD4+ cell counts. Such an approach may have important ramifications in developing countries where access to antiviral drugs is limited and also in early chronic HIV-1 infection when CD4+ cells are still over 300 cells/microL in order to limit the cost and toxicity.
AIDS Vaccines↗